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Abstract: Nanotechnology will affect our lives tremendously over the next decade in very 
different ﬁ  elds, including medicine and pharmacy. Transfer of materials into the nanodimension 
changes their physical properties which were used in pharmaceutics to develop a new innovative 
formulation principle for poorly soluble drugs: the drug nanocrystals. The drug nanocrystals do 
not belong to the future; the ﬁ  rst products are already on the market. The industrially relevant 
production technologies, pearl milling and high pressure homogenization, are reviewed. The 
physics behind the drug nanocrystals and changes of their physical properties are discussed. 
The marketed products are presented and the special physical effects of nanocrystals explained 
which are utilized in each market product. Examples of products in the development pipelines 
(clinical phases) are presented and the beneﬁ  ts for in vivo administration of drug nanocrystals 
are summarized in an overview.
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Introduction
Today nanotechnology is encountered all around our daily lives. Whether it be in the 
production of computer chips (where the need to ﬁ  t more integrated circuits per square 
millimeter is evident to produce chips with more computing power [Kanellos 2005]), 
the increasing ﬁ  eld of biotechnology (where new tools to easily interact with proteins 
in ever smaller sizes are needed [Merkle 1999]) or simply cosmetic research and 
products (where nanonized agents can provide a whole range of beneﬁ  ts [Müller et al 
2006]). In all these ﬁ  elds the need for ever decreased size is common. The nanonization 
of products, whether for medical use (eg, mini robots to clean arteries [Kazimierski 
2005]), the food industry (eg, nanoencapsulated vitamins for so called functional food 
[Velikov 2006]) or the application of drugs for pharmaceutical use, is an important 
factor both on the economical, as well as on the medical or pharmaceutical side. From 
the ﬁ  rst write-through paper (where microencapsulated ink was used as a thin layer 
on the back of the top-sheet and the impact of the typewriter broke the capsules to 
release the ink to the lower sheet [Cinzia De Vita 2004]), nanotechnology has helped to 
achieve progress all around us. This article will focus on nanosized crystals in medical 
application. In drug delivery and clinical applications the technology to nanonize (ie, 
to reduce in size to below 1000 nm) is one of the key factors for modern drug therapy, 
now and in the years to come.
Over the last ten years, the number of poorly soluble drugs has steadily increased. 
Estimates state that 40% of the drugs in the pipelines have solubility problems 
(Speiser 1998). Progress in high throughput screening methods leads to an even 
greater amount of newly discovered drugs that have poor water solubility. Literature 
states that about 60% of all drugs coming directly from synthesis are nowadays poorly 
soluble (Merisko-Liversidge 2002). Poor solubility in water correlates with poor International Journal of Nanomedicine 2008:3(3) 296
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bioavailability. If there is no way to improve drug solubility 
it will not be able to be absorbed from the gastrointestinal 
tract into the bloodstream and reach the site of action.
There are many ways to solubilize certain poorly soluble 
drugs. But these methods are limited to drugs with certain 
properties in regard to their chemistry (eg, solubility in 
certain organic media) or for example to their molecular 
size or conformation (eg, molecules to be incorporated into 
the cyclodextrin [CD] ring structure [Grau 2000]). Apart 
from that, the usage of surfactants or cosolvents is also 
possible, but sometimes leads to increased side effects (eg, 
Cremophor EL (BASF, Ludwigshafen, Germany) increases 
the toxicity of Taxol and HP-ß-cyclodextrin is the cause 
of nephrotoxicity of itraconazole in Sporanox® [Willems 
et al 2001]) and other disadvantages (eg, organic solvent 
residues). The micronization of drug powders to sizes 
between 1 and 10 μm in order to increase the surface area, 
and thus the dissolution velocity, is not sufﬁ  cient to overcome 
bioavailability problems of many very poorly soluble drugs 
of the biopharmaceutical speciﬁ  cation class II. A consequent 
step was to move from micronization to nanonization. Since 
the beginning of the 90s, Elan Nanosystems (San Francisco, 
CA, USA) propagated the use of nanocrystals instead of 
microcrystals for oral bioavailability enhancement, but also 
to use nanocrystals suspended in water (nanosuspensions) 
for intravenous or pulmonary drug delivery.
Deﬁ  nition
Drug nanocrystals are crystals with a size in the nanometer 
range, which means they are nanoparticles with a crystal-
line character. There are discussions about the deﬁ  nition 
of a nanoparticle, which means the size of a particle to be 
classiﬁ  ed as a nanoparticle, depending on the discipline, 
eg, in colloid chemistry particles are only considered as 
nanoparticles when they are in size below 100 nm or even 
below 20 nm. Based on the size unit, in the pharmaceutical 
area nanoparticles should be deﬁ  ned as having a size between 
a few nanometers and 1000 nm (=1 μm); microparticles 
therefore possess a size of 1–1000 μm.
A further characteristic is that drug nanocrystals are 
composed of 100% drug; there is no carrier material as in 
polymeric nanoparticles. Dispersion of drug nanocrystals 
in liquid media leads to so called “nanosuspensions” (in 
contrast to “microsuspensions” or “macrosuspensions”). In 
general the dispersed particles need to be stabilized, such as 
by surfactants or polymeric stabilizers. Dispersion media can 
be water, aqueous solutions or nonaqueous media (eg, liquid 
polyethylene glycol [PEG], oils).
Depending on the production technology, processing of 
drug microcrystals to drug nanoparticles can lead to an either 
crystalline or to an amorphous product, especially when apply-
ing precipitation. In the strictest sense, such an amorphous drug 
nanoparticle should not be called nanocrystal. However, often 
one refers to “nanocrystals in the amorphous state”.
Properties of nanocrystals
The main reasons for the increased dissolution velocity and 
thus increased bioavailability are:
Increase of dissolution velocity by surface 
area enlargement
The size reduction leads to an increased surface area and 
thus according to the Noyes-Whitney equation (Noyes and 
Whitney 1897) to an increased dissolution velocity. There-
fore micronization is a suitable way to successfully enhance 
the bioavailability of drugs where the dissolution velocity is 
the rate limiting step. By moving from micronization further 
down to nanonization, the particle surface is further increased 
and thus the dissolution velocity increases too. In most cases, 
a low dissolution velocity is correlated with low saturation 
solubility (Figure 1).
Increase in saturation solubility
The general textbook statement is that the saturation 
solubility cs is a constant depending on the compound, the 
dissolution medium and the temperature. This is valid for 
powders of daily life with a size in the micrometer range 
or above. However, below a critical size of 1–2 μm, the 
saturation solubility is also a function of the particle size. 
It increases with decreasing particle size below 1000 nm. 
Therefore, drug nanocrystals possess increased saturation 
solubility. This has two advantages:
1.  According to Noyes and Whitney (1897), the dissolution 
velocity is further enhanced because dc/dt is proportional 
to the concentration gradient (cs-cx)/h (cs- saturation solu-
bility, cx - bulk concentration, h - diffusional distance).
2.  due to the increased saturation solubility the concentra-
tion gradient between gut lumen and blood is increased, 
consequently the absorption by passive diffusion 
(Figure 2).
According to the Kelvin equation (Anger 2005), the 
vapor pressure of lipid droplets in a gas phase (aerosol) 
increases with increasing curvature of the surface, which 
means decreasing particle size. Each liquid has its compound 
speciﬁ  c vapor pressure, thus the increase in vapor pressure 
will be inﬂ  uenced by the available compound-speciﬁ  c vapor International Journal of Nanomedicine 2008:3(3) 297
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pressure. The situation of a transfer of molecules from a 
liquid phase (droplet) to a gas phase is in principal identical 
to the transfer of molecules from a solid phase (nanocrystal) 
to a liquid phase (dispersion medium). The vapor pressure 
is equivalent to the dissolution pressure. In the state of 
saturation solubility, there is an equilibrium of molecules 
dissolving and molecules recrystallizing.
This equilibrium can be shifted in case the dissolution 
pressure increases (Figure 3), and thus the saturation solubility 
increases. Identical to liquids with different vapor pressures 
under normal conditions (micrometer droplet size), each drug 
crystal has a speciﬁ  c dissolution pressure in micrometer size. 
Figure 4 shows the increase in cs for the poorly soluble salt 
BaSO4 calculated using the Kelvin equation.
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Figure 2 Comparison of a microcrystal (A) and a nanocrystal (B) and their surface curvature and concentration gradient over the diffusional distance (h).
Abbreviations: cs, drug-saturated water at surface (M, microcrystal; N, nanocrystal); Cx , bulk concentration at diffusional distance; h, diffusional distance. dc / dt ~ (cs – cx) / h.
Used with permission from Junghanns (2006).
Figure 1 Surface enlargement and increase in number of crystals by particle size diminution.
Used with permission from Junghanns (2006).
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Advantages of an amorphous 
particle state
It is well known that amorphous drugs possess a higher 
saturation solubility compared to crystalline drug material. 
A classical example from the literature is chloramphenicol 
palmitate. The polymorphic modiﬁ  cation I has a solubility of 
0.13, the high energy modiﬁ  cation II a solubility of 0.43 and 
the amorphous material of 1.6 mg/ml (Hancock and Parks 
2000; Chong-Hui and Grant 2001). The same is valid for drug 
nanoparticles. Amorphous drug nanoparticles possess a higher 
Figure 3 Increasing dissolution pressure over a ﬂ  at surface, a microparticle, and a nanoparticle.
Abbreviations: p, dissolution pressure; a, ﬂ  at surface; b, microparticle; c, nanoparticle.
Used with permission from Junghanns (2006).
Figure 4 Increase in saturation solubility of BaSO4 in water as a function of the particle size calculated using the Kelvin equation.
Used with permission from Anger (2005).
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saturation solubility compared to equally sized drug nano-
crystals in the crystalline state. Therefore, to reach the highest 
saturation solubility increase, a combination of nanometer 
size and amorphous state is ideal. However, a prerequisite for 
utilization in pharmaceutical products is that the amorphous 
state can be maintained for the shelf life of the product.
Transferring all these facts to drug nanocrystals means 
that optimal drug nanoparticles with the highest increase 
in saturation solubility should have a size of eg, 50 nm or 
20–30 nm, and be amorphous. It can be concluded that the 
size matters regarding the increase in saturation solubility 
and consequently the increase in dissolution velocity caused 
by a higher cs. Of course, it needs to be kept in mind which 
blood proﬁ  le is anticipated with a certain drug. In many cases 
a too-fast dissolution is not desired (creation of high plasma 
peaks, reduction of tmax). For many applications there is the 
need to combine drug nanocrystals with traditional con-
trolled release technology (eg, coated pellets) to avoid fast 
dissolution, excessively high plasma peaks and premature 
tmax, and to reach prolonged blood levels. To summarize, 
the optimal drug nanocrystal size and crystalline/amorphous 
state will depend on:
1.  Required blood proﬁ  le.
2. Administration  route.
3.    Stability of the amorphous state during shelf life of the 
product.
In the case of IV-injected nanocrystals, the size should 
be as small as possible in case the pharmacokinetics of a 
solution are mimicked. In case targeting is the aim (eg, to the 
brain by PathFinder™ technology [Müller et al 1998] or to 
other organs/tissues), the drug nanocrystals should possess a 
certain size to delay dissolution and give them the chance to 
reach the blood – brain barrier (BBB) for internalization by 
the endothelial cells of the BBB targets in the body or other 
target (Kreuter et al 1995) (Table 1).
Production of nanocrystals
There are various possibilities to produce nanocrystals in 
the desired shape and size. Basically three principles can be 
used: milling, precipitation methods and homogenization 
methods, as well as a combination thereof. The industrially 
relevant methods are the top down technologies, ie, starting 
from a large-size drug powder to be reduced in size. The 
bottom up technologies (ie, starting from a dissolved mol-
ecule, precipitation) are currently – to our knowledge – not 
used in the production of commercial products. Reasons 
may include the need for solvent removal, the difﬁ  culty 
in controlling the process, and the fact that many poorly 
soluble drugs are poorly soluble not only in aqueous, but 
also organic media.
Precipitation methods
One of the ﬁ  rst precipitation methods is the preparation of 
hydrosols, which was developed by Sucker, with the intel-
lectual property owned by Sandoz (nowadays Novartis) (List 
and Sucker 1988; Gassmann et al1994). The technology is 
basically a classical precipitation process known as “via 
humida paratum” (VHP). This VHP. process was already 
described in the old pharmacopeia to prepare ointments con-
taining ﬁ  nely dispersed, precipitated drugs. The drug is dis-
solved in a solvent and subsequently added to a nonsolvent, 
leading to the precipitation of ﬁ  nely dispersed drug nano-
crystals. One needs to bear in mind that these nanocrystals 
need to be stabilized in order not to grow to the micrometer 
range. In addition, the drug needs to be soluble in at least one 
solvent, which creates problems for newly developed drugs 
that are insoluble in both aqueous and organic media. These 
are some reasons why, to our knowledge, this technology has 
not been applied to a product as yet.
Another precipitation method is the preparation of 
amorphous drug nanoparticles, for example, as carotene 
nanoparticles in the food industry (Shackleford et al 2003), 
eg, Lucarotin® or Lucantin® (BASF). A solution of the 
carotenoid, together with a surfactant in a digestible oil, are 
mixed with an appropriate solvent at a speciﬁ  c temperature. 
To obtain the solution a protective colloid is added. This 
leads to an O/W two phase system. The carotenoid stabilized 
by the colloid localizes in the oily phase. After lyophiliza-
tion X-ray analyzes shows that approximately 90% of the 
carotenoid is in an amorphous state. This technology is used 
for pharmaceuticals by Soliqs (Ludwigshafen, Germany) 
and advertised under the trade name NanoMorph®.
Milling methods
The classical NanoCrystals® technology uses a bead or a 
pearl mill to achieve particle size diminution. Ball mills are 
already known from the ﬁ  rst half of the 20th century for the 
Table 1 Properties of nanocrystals
1 – Size below 1 μm
2 – 100% drug, no carrier
3 – Generally needed to be stabilized
4 – Crystalline or amorphous structure
5 – Increase of dissolution velocity
6 – Increase in saturation solubility
7 – Amorphous particle state offers advantagesInternational Journal of Nanomedicine 2008:3(3) 300
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production of ultra ﬁ  ne suspensions (Pahl 1991). Milling 
media, dispersion medium (generally water), stabilizer and 
the drug are charged into the milling chamber. Shear forces 
of impact, generated by the movement of the milling media, 
lead to particle size reduction. In contrast to high pressure 
homogenization, it is a low energy milling technique. Smaller 
or larger milling pearls are used as milling media. The pearls 
or balls consist of ceramics (cerium or yttrium stabilized zir-
conium dioxide), stainless steel, glass or highly crosslinked 
polystyrene resin-coated beads. Erosion from the milling 
material during the milling process is a common problem 
of this technology. To reduce the amount of impurities 
caused by erosion of the milling media, the milling beads are 
coated (Bruno et al 1992). Another problem is the adherence 
of product to the inner surface area of the mill (consisting 
mainly of the surface of the milling pearls and the surface 
of the mill itself).
There are two basic milling principles. Either the milling 
medium is moved by an agitator, or the complete container 
is moved in a complex movement leading consequently to 
a movement of the milling media. When one assumes that 
76% of the volume of the milling chamber (maximum value 
at hexagonal packaging) are going to be ﬁ  lled with mill-
ing material, larger batches are difﬁ  cult to produce when 
moving the complete container, so mills using agitators 
are used for large sized mill for large batches. The milling 
time depends on many factors such as the surfactant con-
tent, hardness of the drug, viscosity, temperature, energy 
input, size of the milling media. The milling time can last 
from about 30 minutes to hours or several days (Merisko-
Liversidge et al 2003). This technology is an important 
particle size reduction technology which is proven by four 
FDA-approved drugs using it, which will the subject later 
in this text.
Homogenization methods
When producing nanocrystals using homogenization methods, 
there are three important technologies namely: Microﬂ  uidizer 
technology (IDD-P™™ technology), Piston gap homogeniza-
tion in water (Dissocubes® technology) and in water mixtures 
or in nonaqueous media (Nanopure® technology).
The Microfluidizer technology can generate small 
particles by a frontal collision of two ﬂ  uid streams under 
pressures up to 1700 bar (Bruno and McIlwrick 1999). This 
leads to particle collision, shear forces and also cavitation 
forces (Tunick et al 2002). It can be achieved with jet stream 
homogenizers such as the microﬂ  uidizer (Microﬂ  uidizer®, 
Microﬂ  uidics Inc.). The collision chamber can be designed 
in two shapes, being either Y-type or Z-type. Surfactants are 
required to stabilize the desired particle size. Unfortunately 
,a relatively high number of cycles (50 to 100 passes) are 
necessary for a sufﬁ  cient particle size reduction. SkyePharma 
Canada Inc. (formerly RTP Inc.) uses this principle for their 
Insoluble Drug Delivery – Particles (IDD-P™) technology 
to achieve the production of submicron particles of poorly 
soluble drugs.
In contrast, the Dissocubes® technology employs pis-
ton-gap homogenizers. The technology was developed 
by Müller and colleagues (1995, 1999) and later acquired 
by SkyePharma PLC. It is the production of nanoparticle 
suspensions in water at room temperature. A drug powder 
is dispersed in an aqueous surfactant solution and subse-
quently forced by a piston through the tiny homogenization 
gap with pressures ranging up to 4000 bar, typically 1500 
to 2000 bar (Figure 5). The width of the homogenization 
gap, depending on the viscosity of the suspension and the 
applied pressure, ranges from approximately. 5 to 20 μm 
(Möschwitzer 2005). The resulting high streaming velocity 
of the suspension causes an increase in the dynamic pressure 
which is compensated by a reduction in the static pressure 
below the vapor pressure of the aqueous phase (according 
to Bernoulli’s law [Müller et al 1995]). Formation of gas 
bubbles occurs because the water starts boiling at room 
temperature. These gas bubbles collapse immediately when 
the liquid leaves the homogenization gap being again under 
normal air pressure of 1 bar.
This phenomenon of formation and implosion of the gas 
bubbles is called cavitation resulting in shockwaves. The 
drug particles are reduced in size due to high shear forces, 
turbulent ﬂ  ow and the enormous power of these shockwaves 
(Muller et al 2001).
Of course, the use of water can have disadvantages, eg, 
hydrolysis of water-sensitive drugs and problems during 
subsequent drying steps (such as the removal of too much 
water). When applied to drugs with a low melting point, 
the drying process may quire expensive techniques like 
lyophilization. Therefore the technology is most suitable 
for the formulation of aqueous suspensions of nanocrystals 
(Figure 6) (Müller et al 2003).
Another approach using the piston-gap homogenizer is 
the Nanopure® technology, owned and developed by Pharma-
Sol GmbH in Berlin. The technology uses dispersion media 
with a low vapor pressure and optionally homogenization at 
low temperatures. The cavitation in the homogenization gap 
is very little or nonexistent. Even without cavitation, the size 
diminution was sufﬁ  cient (Bushrab and Müller 2003). The International Journal of Nanomedicine 2008:3(3) 301
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Figure 5 Basic principle of high pressure homogenization using a piston gap homogenizer.
Used with permission from Junghanns (2006).
Figure 6 Scanning electron microscopic picture of a nanosuspension prepared with high pressure homogenization.
Used with permission from Möschwitzer (2005).
remaining shear forces, particle collisions and turbulences 
are sufﬁ  cient to achieve nanoparticles. The optional low 
temperatures while homogenizing allow the processing of 
temperature labile drugs (Müller et al 2002). It is possible to 
carry out the whole process in nonaqueous media to protect 
drugs from hydrolysis. Usage of oils, PEG or hot-melted 
polyethylene glycols can be directly ﬁ  lled into gelatin or 
HPMC capsules (Keck et al 2004).
In order to give a complete overview of the available 
technologies the following methods are also available. 
The company Baxter uses for its NanoEdge™ technology 
a precipitation step with subsequent annealing step by 
drug suspension
piston
valve seat
homogenization gap
product outlet
valve
drug nanocrystals
pInternational Journal of Nanomedicine 2008:3(3) 302
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applying high energy, eg, high shear and/or thermal 
energy (Kipp et al 2003). PharmaSol uses in its Nanopure 
XP technology a pre-treatment step with subsequent 
homogenization to produce particles well below 100 nm 
(Müller and Moeschwitzer 2005). Drug nanocrystals with a 
size of about 50 nm and below are distinctly smaller than the 
wavelength of the visible light, and so the nanosuspensions 
are translucent.
Among other technologies, the following supercritical 
ﬂ  uid methods are mentioned for reasons of completeness only. 
Rapid expansion of supercritical solution (RESS), rapid expan-
sion from supercritical to aqueous solution (RESAS), solution-
enhanced dispersion by the supercritical ﬂ  uids (SEDS), spray 
freezing into liquid (SFL), evaporative precipitation into aque-
ous solution (EPAS), and aerosol solvent extraction (ASES) 
(Müller and Bleich 1996; Lee et al 2005).
Products in the market
All nanocrystals in the ﬁ  rst four products were produced using 
the pearl mill technology by Elan Nanosystems. Prerequisite 
was the availability of production facilities at sufﬁ  ciently large 
scale. In general candidates of ﬁ  rst choice for Nanocrystal® 
technology are drugs with a relatively low dose (Table 2).
Rapamune®
Rapamune® contains sirolimus (SRL, rapamycin) as the 
active drug, which is derived from Streptomyces hygro-
scopicus (actinomycetes) (Figures 7, 8). SRL is a macrocyclic 
immunosuppressive drug with a molecular weight of 914.2 
and is related to tacrolimus which is produced from different 
species of Streptomyces.
SRL is being used mostly in a combination with cyclo-
sporine or steroids to avoid organ rejection in patients after 
a kidney transplant. In cardiology SLR is used because of 
its antiproliferative effect to avoid a reoccurring constriction 
(restenosis) caused by a hyperplasia of the inner vascular after 
implantation of a stent into the vessels around the heart.
The mechanism of action of SLR is different from cyclo-
sporine and tacrolimus. SLR inhibits several cytokine induced 
signal transduction pathways by complexing the mTOR 
(mammalian Target of Rapamycin) protein, which is a 282 
kDA phosphatidyl 3 kinase. Therefore the subsequent acti-
vation and the protein synthesis of the S6-Kinase (p70SK6) 
is not triggered and the activation of the ribosomal protein 
S6 does not occur. The inhibition of mTOR circumvents the 
activation of the p34cdc2 kinase and thus the complexation 
with Cyclin E. This results in an inhibition of the T-cell 
transfer from the G1-phase to the S-phase of the cell-cycle 
(Sehgal 1998).
Rapamune was the ﬁ  rst marketed product introduced 
in 2000 by Wyeth Pharmaceuticals (Madison, NJ). It is 
available in two formulations, as oral suspensions and as 
a tablet. The tablet has the advantage of being more user-
friendly. Comparing the oral bioavailability of solution and 
nanocrystal tablet, the bioavailability of the nanocrystals is 
21% higher compared to the solution. The oral single dose of 
Rapamune is 1 or 2 mg, the total tablet weight being approxi-
mately 365 mg for 1 mg formulation and approximately. 
370 mg for the 2 mg formulation. This means it contains a 
very low percentage of its total weight as nanocrystals. An 
important point is that the drug nanocrystals are released 
from the tablet as ultra ﬁ  ne nanosuspension. In the event that 
Table 2 Advantages and disadvantages of different methods for the production of nanocrystals
Technology Advantages Disadvantages
Precipitation - ﬁ  nely dispersed drug - needs to be stabilized
- good control of desired size - organic solvent residue
-   not universally applicable, only drugs with certain 
properties are possible (eg, soluble in at least one 
solvent)
Milling - low energy technique - residue from milling media
- proven by 4 FDA approved drugs - can be a slow process (several days)
- needs to be stabilized
-   large batches difﬁ  cult to produce due to size of 
milling chamber
Homogenization - universally applicable - high energy technique
- no problem with large batches - great experience needed
- fast method (several minutes possibly)
- water free production possibleInternational Journal of Nanomedicine 2008:3(3) 303
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crystal aggregation takes place to a pronounced extent, the 
dissolution velocity and subsequently the oral bioavailability 
of the BSC II drugs will be reduced. Therefore, there is an 
upper limit to load tablets with nanocrystals. In case the limit 
is exceeded and nanocrystals get in contact with each other 
within the excipient mixture of the tablet, the nanocrystals 
might fuse to larger crystals under the compression pressure 
during tablet production. For drugs with a low oral single 
dose such as sirolimus in Rapamune, incorporation into 
tablets causes few or no problems. A total nanoparticle load 
of less than 1% is well below the percentage being critical 
(Bushrab 2005).
The main advantages of the nanocrystal technology in this 
product are the user friendliness and the higher bioavailability 
in comparison to the oral solution. As discussed previously, 
a smaller particle size leads to greater solubility and larger 
surface area, consequently increased dissolution velocity and 
thus greater bioavailability.
Emend®
The second product on the market was Emend®, introduced 
in 2001 by Merck (Winehouse Station, NJ) (Figures 9, 10). 
The drug is aprepitant, used for treatment of emesis (single 
dose is either 80 or 125 mg).
Aprepitant is a selective, high-afﬁ  nity antagonist of 
human substance P/neurokinin 1 (NK 1) receptors. Aprepi-
tant has little or no afﬁ  nity for serotonin (5-HT 3), dopamine, 
and corticosteroid receptors, the targets of existing therapies 
for chemotherapy-induced nausea and vomiting (CINV).
Aprepitant has been shown in animal models to inhibit 
emesis induced by cytotoxic chemotherapeutic agents, such 
as cisplatin, via central actions. Aprepitant augments the anti-
emetic activity of the 5-HT 3-receptor antagonist ondansetron 
and the corticosteroid dexamethasone and inhibits both the 
acute and delayed phases of cisplatin-induced emesis.
Aprepitant will only be absorbed in the upper gastrointes-
tinal tract (Shimizu 2003). Bearing this in mind nanoparticles 
proved to be ideal to ideally exploit this narrow absorption 
window. The large increase in surface area due to nanonization 
leads to rapid in vivo dissolution, fast absorption and increased 
bioavailability (Möschwitzer and Müller 2004a, 2004b). The 
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Figure 8 Packaging of Rapamune®. Figure 10 Packaging of Emend®.International Journal of Nanomedicine 2008:3(3) 304
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formulation of a tablet from micronized bulk powder made 
much higher doses necessary, leading to increased side effects 
(eg, other serotonin receptor induced effects like dizziness) 
(Wua et al 2004). The drug nanocrystals are contained within 
a hard gelatin capsule as pellets. Aprepitant was formulated 
this way in order to make the drug easy to handle by healthcare 
providers and patients as capsules. In addition, the pellets can 
be administered via a stomach tube. Currently studies are 
being undertaken to evaluate the change in pharmacokinetics 
(if any) between the pellets and the capsules. One needs to 
bear in mind that a higher loading of the tablet with more than 
125 mg drug in a 400 mg tablet is near the critical amount, 
which is about 30%. If the total drug content exceeds 30%, 
the possibility of drug nanocrystals directly touching each 
other and fusing to larger crystals is enhanced. There are 
special methods and technologies required to produce high 
nanocrystal-loaded tablets. By applying this, up to 90% nano-
crystal powder would be loaded into tablets (Möschwitzer 
and Müller 2005).
This example of aprepitant demonstrates once again the 
importance of an increased bioavailability through nanon-
ization. In case of a drug with a narrow absorption window 
which is also poorly soluble it is important to reduce the 
particle size to a size threshold that will make the drug bio-
available by enhancing the solubility.
Tricor®
Tricor® is being marketed by Abbott Laboratories and the 
active ingredient is fenoﬁ  brate, being available in 48 mg 
and 145 mg tablets (Figures 11, 12). Tricor is indicated as 
adjunctive therapy to diet in adult patients with primary 
hypercholesterolemia or mixed dyslipidemia (Fredrickson 
types IIa and IIb) to increase high-density lipoprotein choles-
terol (HDL-C), reduce triglycerides (TG), reduce low-density 
lipoprotein cholesterol (LDL-C), reduce total cholesterol 
(Total-C), and reduce apolipoprotein B (Apo B).
Fenoﬁ  brate is metabolized into fenoﬁ  bric acid and activates 
the peroxisome proliferator-activated receptor α (PPARα). 
Fenoﬁ  brate increases the lipolyses and the elimination of 
TH-rich particles from the plasma by activating the lipoprotein 
lipase and reducing the production of apoprotein C-III, which 
is an inhibitor of the lipoprotein lipase activity.
The subsequent fall in TG produces an alteration in size 
and composition of LDL from small dense particles (thought 
to be atherogenic due to their susceptibility to oxidation) 
to large buoyant particle. These particles have a greater 
afﬁ  nity for cholesterol receptors and are catabolized rapidly 
(Witztum 1996).
In types IIa and IIb hyperlipidemia, LDL-C also decreases, 
in contrast to type IV hyperlipidemia where LDL-C often 
increases. The activation of PPARα also induces an increase 
in the synthesis of apoproteins A-I, A-II and HDL-C (Inves-
tigators 2001).
In normal and hyperuremic individuals, fenoﬁ  brate also 
reduces the serum uric acid levels by increasing the urinary 
excretion of uric acid (TriCor® tablets package insert; Abbott 
Labs, Wiesbaden-Delkenheim, Germany).
In general, the uptake from of the gut lumen and thus 
the bioavailability of fenoﬁ  brate is depending on whether 
the patient is in the fed or nonfed state. The absorption of 
fenoﬁ  brate in fed patients is up to 35% higher than in nonfed 
patients. The nanocrystal technology makes the fenoﬁ  brate 
independent of meals. Plasma levels in fed and fasting 
condition are bioequivalent (data on ﬁ  le, Abbott Labs).
Fenoﬁ  brate is a lipophilic compound and practically 
insoluble in water. Having no ionizable group, the solubil-
ity of fenoﬁ  brate was not inﬂ  uenced by changes in pH value 
through the application of food. The enhanced absorption of 
fenoﬁ  brate in fed patients can be explained with the avail-
ability of lipids and other surfactants (eg, cholesterol) in the 
food, thus solubilizing the fenoﬁ  brate. By nanonizing the 
drug, the solubility is enhanced, making it bioequivalent in 
fed and fasting conditions.
Another product using nanocrystals to make an advanced 
fenofibrate is Triglide®, which is produced using the 
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Figure 11 Structural formula of fenoﬁ  brate.
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IDD-P®-technology (as discussed before) from Skyepharma 
and is marketed by Sciele Pharma Inc (Atlanta, GA).
Megace ES®
In Megace ES® (ES stands for Enhanced Stability) (megestrol 
acetate) introduced by Par Pharmaceutical Companies, Inc. 
(Spring Valley, NY), who licensed the Megace name from 
Bristol-Myers Squibb (New York, NY), the Nanocrystal 
technology leads to several advantages (Figures 13, 14).
Megestrol was synthesized in England in 1963. Initially 
developed as a contraceptive, it was ﬁ  rst evaluated in breast 
cancer treatment in 1967. Megestrol is a synthetic progestin 
and has the same physiologic effects as natural progesterone. 
The biochemical mechanism of progestin antitumor activity 
is not well known but may involve interaction with progester-
one and glucocorticoid receptors, and androgenic properties. 
Megestrol also has direct cytotoxic effects on breast cancer 
cells in tissue culture and suppresses luteinizing hormone 
release from the pituitary. It is mainly used to improve weight 
gain and appetite in patients undergoing chemotherapy or 
suffering from an HIV infection. It can also be used to treat 
psychologically induced anorexia. The precise mechanism of 
megestrol’s antianorexic and anticachetic effects is unknown 
(Prescribing Information 2005).
Megestrol is well absorbed in the gastrointestinal tract 
but absorption varies. A bioavailability study comparing 
the peak plasma concentration and extent of absorption of 
Megace ES and megestrol acetate oral suspension revealed 
that in unfed patients, the bioavailability of Megace ES is 
minimally reduced while there was a substantial food effect 
for megestrol acetate oral suspension (Femia 2005).
The improved rate of dissolution again resulting from 
the particle dimensions in the nanometer range leads 
to an enhanced bioavailability in people in fasted state 
(NanoCrystal®-Technology-Group 2005).
The nanonized drug can be formulated in less volume, 
so the single dose the patient has to take (daily dose 625 mg 
of megestrol in 5 ml of ﬂ  uid) is reduced by the factor four 
compared to the oral solution available. This reduced vol-
ume and the improved bioavailability lead to a better patient 
compliance due to the possibility of ﬂ  exible dosing in order 
to provide effective appetite stimulation and weight gain.
Another advantage is the reduced viscosity of the Megace 
ES formulation, which also leads to increased patient com-
pliance. This viscosity reduction is a direct effect of the 
reduction of the particle size (no or little viscosity enhance-
ment necessary to prevent sedimentation) (Data on ﬁ  le. Par 
Pharmaceutical Companies, Inc.) (Table 3).
Products in pipeline
In general, it can be stated that the advantages of the nano-
crystal technology can be applied to many other poorly 
soluble drugs as well. There are already several products 
close to being marketed or in clinical trials.
Information about these drugs and products is sparingly 
available due to high risks for knowledge leaks and fear of 
competitors in the pharmaceutical industry, but the following 
examples give an indication of potential future products:
Semapimod® (cytokine, pharmasciences)
Semapimod® is a synthetic guanylhydrazone that inhibits 1) 
signal transduction pathways by preventing phosphorylation 
of p38 MAP kinase and JNK; 2) production of the 
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Figure 13 Structural formula of megestrol acetate.
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proinﬂ  ammatory cytokines TNF-alpha, IL-1, IL-6. MIP-1 
alpha, MIP-1 beta; and 3) production of nitric oxide. These 
signal transduction pathways and proinﬂ  ammatory molecules 
are known to be active in various inﬂ  ammatory and autoim-
mune diseases. Semapimod may therefore have widespread 
applications in these diseases. In animal models, Semapi-
mod has shown protective activity against a wide variety 
of conditions, ranging from stroke to inﬂ  ammatory bowel 
disease. A Phase I study in cancer patients demonstrated 
the safety of the compound and conﬁ  rmed its activity in 
preventing the synthesis of TNF-alpha in humans. CPSI 
conducted successful proof-of-principle studies in psoriasis 
and Crohn’s disease. The company also employs the nano-
crystal technology from Elan Nanosystems in order to make 
this poorly soluble drug bioavailable (cited after http://www.
cytokinepharmasciences.com).
PAXCEED™
Angiotech Pharmaceuticals Inc, (Vancouver, BC) has devel-
oped an intravenous (or systemic) treatment for rheumatoid 
arthritis. Treating patients with chronic inﬂ  ammatory dis-
eases require that side effects of systemic treatments be mini-
mized. They have produced a cremophor EL-free systemic 
paclitaxel formulation, PAXCEED™ (paclitaxel, Angiotech 
Pharmaceuticals, Inc.), for patients with active, widespread 
diseases. This formulation reduces the incidence of hyper-
sensitivity reactions. In addition, the doses of PAXCEED™ 
used for these indications are signiﬁ  cantly lower when used 
as an anti-proliferative.
PAXCEED™ is a metalloproteinase inhibitor and 
therefore has the potential to not only stop inﬂ  ammation, 
but also protect the cartilage. In addition, PAXCEED™ 
is synergistic, not competitive, to recently developed anti-
TNF therapies.
At this moment there is no information available which 
nanotechnology was used to produce the resulting nano-
crystals. The low solubility of Paclitaxel and the proclaimed 
absence of Cremophor EL give a good indication (cited after 
http://www.angiotech.com).
Theralux™
Thymectacin is currently in Phase I/II clinical develop-
ment. Theralux™ (thymectacin, Celmed BioSciences Inc, 
Saint-Laurent, QC), a photodynamic-based therapy, is being 
evaluated in three therapeutic areas: the prevention of graft-
versus-host disease (GvHD), the treatment of autoimmune 
diseases by extracorporeal photochemotherapy (ECP) and the 
eradication of cancerous cells from bone marrow transplants 
in non-Hodgkin’s lymphoma (NHL). The company also 
employs the nanocrystal technology from Elan Nanosystems. 
Thymectacin is poorly soluble and thus needs to be formulated 
as nanocrystals to become bioavailable.
The Theralux system consists of a photosensitive drug 
and a device designed to eliminate certain unwanted cells 
(used outside the body). The drug, TH9402, is Celmed’s 
proprietary product that is preferentially retained in cancer 
cells and activated T cells. When TH9402 is administered 
to a stem cell graft, it enters and is retained in the cancerous 
cells and activated T cells, but not other normal cells such 
as stem cells, progenitors and precursors. When the cells 
retaining the drug are exposed to visible light using Celmed’s 
Theralux device, the drug undergoes photodynamic activa-
tion leading to the death of the unwanted cells. The process 
is conducted ex vivo (outside the body), thus minimizing side 
effects and toxicity. Once the blood sample has been purged 
of the unwanted cells, it is reinfused into the patient, who 
meanwhile has undergone high-dose chemotherapy (cited 
after: http://www.newbiotics.com).
Table 3 Overview of current state of development of drugs using the Nanocrystal® technology or others
Tradename Drug Indication Applied technology Company Status
Rapamune® Rapamycin Immunesuppressive Nanocrystal® élan Wyeth marketed
Emend® Aprepitant Anti emetic Nanocrystal® élan Merck marketed
Tricor® Fenoﬁ  brate Hypercholesterolemia Nanocrystal® élan Abbott marketed
Megace ES® Megestrol Anti anorexic Nanocrystal® élan Par Pharmaceutical
Companies
marketed
Triglide® Fenoﬁ  brate Hypercholesterolemia IDD-P® Skyepharma Sciele Pharma Inc. marketed
Semapimod® Guanylhydrazone TNF-α inhibitor own Cytokine Pharmasciences Phase II
Paxceed® Paclitaxel Anti inﬂ  ammatory unknown Angiotech Phase III
Theralux® Thymectacin Anti cancer Nanocrystal® élan Celmed Phase II
Nucryst® Silver Anti bacterial own Nucryst Pharmaceuticals Phase II
Used with permission from Junghanns (2006).International Journal of Nanomedicine 2008:3(3) 307
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Table 4 In vivo effects of nanocrystals
Used with permission from Junghanns (2006).
Complete/fast dissolution in a narrow 
absorption window (eg, Emend)
Compared with solutions Nanosuspension can administer a high dose of drug in a very
small volume (=volume reduction) but provide an identical bioavailability as a solution
(eg, Megace ES) Nanosuspension with a 40% solid content can be produced
Dissolution so fast to mimick adminstered
solution (eg, Rapamune)
Saturation solubility of poorly water
soluble but lipid soluble drug as NC in
water as high as drug dissolved in food
(fats/oils) (eg, Tricor)
C.1 fat/oil droplets with drug
C.2 NC drug in water
Adhesiveness to gut wall avoids effects
of fed/fasted condition (ie, no or little
variation in bioavailability) (eg, Tricor)
1=solution of drug in 20 ml
2=concentrated Nanosuspension
(12.5%) in 5 ml
Both flasks contains the same drug
dose, eg, 625 mg International Journal of Nanomedicine 2008:3(3) 308
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NUCRYST®
With their own nanotechnology, Nucryst Pharmaceuticals 
(Wakeﬁ  eld, MA) has developed a way to produce silver 
nanoparticles which can be used in antimicrobiological 
coatings for medical use. They are also working on their 
substance NPI 32101 in a cream formulation, which is in 
clinical development to treat atopic dermatitis (Bhol et al 
2004; Bol and Schechter 2005a). NPI 32101 is free standing 
silver nanocrystals, which can be combined with pharmaceu-
tical carriers such as creams, gels, solutions, or tablets to form 
prescription drugs. Laboratory studies have demonstrated 
NPI 32101’s anti-inﬂ  ammatory and antimicrobial properties 
(Bhol and Schechter 2004; Lyczak and Schechter 2005). 
NUCRYST’s in vitro and in vivo research results suggest 
that NPI 32101 offers great promise for a range of commer-
cial pharmaceutical products. The NPI 32101 is currently in 
clinical phase II (Bhol and Schecter 2005b).
Apart from the products already mentioned there are 
drugs such as naproxen which are also being investigated 
for formulation as nanosuspension or nanocrystals (eg, for 
fast action onset and reduced gastric irritancy) (Liversidge 
and Conzentino1995). However, it requires more sophisti-
cated formulation technology to ensure the release of the 
drug nanocrystals as ﬁ  ne suspension when incorporated in 
a tablet in such a relatively high concentration (single dose: 
250 mg). It must be noted that the tablet size (weight) has 
to be acceptable for the patient and that a dosing with two 
tablets should be avoided for reasons of patient compliance 
and marketing.
Conclusions
As the examples have shown, nanocrystal technology offers 
great beneﬁ  ts with only a few minor drawbacks (Table 4). It 
is clearly ideally suited for drugs with solubility problems. 
Particle size diminution and the resulting increase in particle 
surface, curvature, saturation solubility, and consequently the 
increased dissolution velocity, are important factors.
Solubility enhancement alone is not the only important 
factor. It becomes even more important when a drug has a 
narrow therapeutic window where it can be absorbed. In 
these cases the increased solubility and dissolution velocity 
lead to an acceptable bioavailability.
In addition, the nanocrystal technology enables formu-
lations to be developed without the need of problematic 
surfactants (eg, Cremophor EL) which may cause enhanced 
side effects or adverse reactions. Furthermore, nanocrystals 
allow for a fast action onset, as the drug is absorbed quickly 
due to the fast dissolution of the nanoparticles. This is an 
advantage, especially for drugs which need to work fast (eg, 
naproxen for headache relief).
As discussed the enhanced solubility also leads to an iden-
tical or very similar absorption in fed and fasted conditions. 
Drugs which normally require food to become soluble will 
be bioequivalent as nanocrystals in fed and fasted states.
If it is necessary to give a large dosage in order to achieve 
reasonable blood levels for poorly soluble drugs resulting in 
increased side effects, the nanocrystal technology allows for 
smaller doses and thus decreased side effects.
Disadvantages are the sometimes long production times, 
eg, in pearl milling. However, new patents to accelerate 
large scale production have just been filed, eg, H42 
(Müller and Moeschwitzer 2005). In addition, improved 
technologies are required to be able to produce tablets with 
high drug nanocrystal loads to formulate high dose drugs 
in – preferentially – one single tablet.
In future, more drugs will be poorly soluble and thus 
require smart formulation technologies to make them soluble 
and bioavailable. An increased awareness in patients not 
willing to suffer from unnecessary side effects will lead to an 
increased number of products using nanocrystals to reduce 
these risks. By modifying the nanocrystal surface it is possible 
to achieve a prolonged or a targeted release. This will be an 
important part of the work for the nanoparticles in future.
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